Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations Authors: Changwei Wang, Prithwish Ghosh, Shicheng Jin, Longchuan Bai, Angelo Aguilar, Donna McEachern, Mi Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang Published: 2026 ABSTRACT KRAS G12D and G12V mutants account for >50% of human cancers carrying a mutated KRAS protein, and targeting KRAS proteins by induced protein degradation represents an attractive cancer therapeutic strategy. Herein, we present the design, synthesis, and evaluation of PROTAC KRAS degraders using a novel cereblon ligand, which led to the discovery of CW-10201 as a promising KRAS degrader. CW-10201 effectively induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cells and attained IC50 values of 2–4 nM in inhibition of cell growth in cancer cell lines carrying KRASG12D or KRASG12V mutation. It demonstrated excellent pharmacokinetic and pharmacodynamic properties in mice. CW-10201 was capable of attaining tumor regression in the SW1990 KRASG12D mutated xenograft tumor model and effectively inhibited tumor growth in the SW620 KRASG12V xenograft tumor model in mice at well-tolerated doses. CW-10201 represents a promising KRASG12D and KRASG12V degrader for extensive evaluation and optimization for the treatment of human cancers. Introduction KRAS is one of the most frequently mutated oncogenes in human cancers, playing a critical role in cancer growth, progression and metastasis. KRAS mutations occur in more than 200,000 new cancer cases annually in the United States alone, and are found globally in approximately 20% of all human cancers. Despite being among the first oncogenes discovered, KRAS has long been considered “undruggable” because of its shallow binding pocket, extremely high affinity for GTP, and the rapid cycling between its active GTP-bound (ON) and inactive GDP-bound (OFF) states. After more than three decades of efforts, a major breakthrough was made by Shokat and colleagues on the discovery of small-molecule inhibitors of KRASG12C targeting the “switch II” pocket, which paved the way for the clinical development and ultimate FDA approvals of two KRASG12C inhibitors, namely Sotorasib and Adagrasib. However, since the G12C mutation represents only about 12% of all KRAS mutations in cancer patients, there is an urgent need to develop agents to target other KRAS mutations, particularly KRASG12D and KRASG12V, which together account for more than half (52.2%) of all KRAS-driven cancers. Intense research efforts in recent years have now led to the development of small-molecule inhibitors targeting other KRAS mutations. MRTX1133 was designed as the first-in-class selective KRASG12D inhibitor based upon Adagrasib. Although the clinical development of MRTX1133 was discontinued due to pharmacokinetic challenges, the preclinical data for MRTX1133 nevertheless demonstrated the feasibility of targeting KRASG12D and potentially other KRAS mutations. Indeed, based upon the chemical structure of MRTX1133, different classes of KRASG12D have been discovered and a number of them have been advanced into early clinical development, with representative compounds shown in Figure . Additionally, KRASG12V preferred inhibitors and inhibitors targeting multiple KRAS mutants (pan KRAS mutant inhibitors) have been reported, and several such inhibitors are now in early stages of clinical development. , Chemical structures of representative “molecular glue” pan-KRAS inhibitor RMC-6236 (1), KRASG12C inhibitor divarasib (2), KRASG12D inhibitor MRTX1133 (3), and KRASG12D degraders ASP3082 (4), compound 8 (5) and RP03707 (6) and pan-KRAS degraders ACBI3 (7) and compound 1 (8). RMC-6236 (Daraxonrasib) was discovered as a pan KRAS inhibitor with a distinct mechanism of action as compared to Sotorasib, Adagrasib, MRTX1133 and other conventional KRAS inhibitors. RMC-6236 acts as a “molecular glue”, first binding to the chaperone-like protein cyclophilin A and then forming a trimolecular complex with active RAS to effectively block downstream effector binding and oncogenic signaling. In addition to KRAS mutants, RMC-6236 also effectively inhibits wild-type KRAS, as well as NRAS and HRAS and is therefore a nonselective RAS inhibitor. RMC-6236 has demonstrated promising antitumor efficacy in early clinical trials with an acceptable toxicity profile , and is currently in Phase 3 registrational trials for the treatment of previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and other types of human cancer. , Based upon RMC-6236, highly selective KRASG12D, KRASG12C and KRASG12V inhibitors were also developed. , In recent years, proteolysis targeting chimeras (PROTACs) have been employed as a powerful strategy for the discovery and development of new therapies against those traditionally difficult or “undruggable” targets. Through induced protein degradation, PROTAC KRAS degraders can effectively inhibit KRAS signaling, block KRAS scaffolding functions, and enhance antitumor immune responses. , Indeed, using genetically engineered mouse models, Marina et al. demonstrated that KRAS oncogene ablation induces profound tumor regression by preventing the rapid emergence of resistant cells. In a direct comparison study, the pan-KRAS degrader MCB-36 exhibited more sustained suppression of both KRAS and ERK signaling than the corresponding pan-inhibitor MCB-294. To date, four KRASG12D-selective degraders and two pan-KRAS degraders have entered clinical trials. As a pioneer in the field, Astellas Pharma has advanced two G12D-selective degraders, ASP3082 (NCT05382559) (4, Figure ) and ASP4396 (NCT06364696). Data disclosed at the 2024 ESMO meeting showed that ASP3082 (4) exhibited an acceptable safety profile and promising antitumor activity. In 2025, PAQ Therapeutics and Arvinas have advanced their respective KRASG12D selective degraders, PT0253 (NCT06797336) and ARV-806 (NCT07023731), into Phase 1 clinical development. , In addition, several other classes of KRASG12D selective degraders have been reported in the literature, − with some now in advanced stages of preclinical development. KRASG12V is the second most prevalent KRAS mutation, accounting for approximately 48,400 new cases each year in the USA. As compared to the development of selective KRASG12D inhibitors and degraders, development of selective KRASG12V inhibitors and degraders have been relatively lagging. In a pioneering study, Popow and colleagues reported the discovery and extensive evaluations of a potent and efficacious pan KRAS degrader ACBI3. It was demonstrated that ACBI3 was capable of selectively degrading 13 of 17 of the most common KRAS mutants. KRAS degradation can yield more profound and sustained pathway suppression across a broad spectrum of KRAS mutant cell lines, effectively killing cancer cells while sparing wild-type models. In both GP2d (KRASG12D) and RKN (KRASG12V) xenograft models, ACBI3 was well tolerated and attained tumor regression with daily, intravenous administration. While ACBI3 was not suitable for clinical development, the preclinical data nevertheless demonstrated the feasibility of discovering degraders targeting those most common KRAS mutants. Indeed, a number of pan KRAS mutant degraders have been disclosed in patents. , To date, two pan-KRAS degraders, namely ASP5834 and PT0511 have been advanced into clinical development (NCT07094204) and (NCT07300150). Despite these major progresses made in the development of KRAS degraders, there is considerable need to develop additional new, potent and highly efficacious KRAS degraders, particularly KRAS degraders capable of effectively targeting both KRASG12D and KRASG12V mutations. While ASP3082, a KRASG12D selective degrader, has been recently advanced into a Phase 3 clinical trial in combination with chemotherapy (mFOLFIRINOX or NALIRIFOX) for the treatment of pancreatic cancer, ASP3082 has a relatively weak degradation potency , and all other PROTAC KRAS degraders are still in early stages of clinical development or in preclinical development. Second, while ACBI3 demonstrated profound antitumor activity in xenograft tumor models carrying KRASG12D and KRASG12V mutations, daily, intravenous dosing was required, suggesting that extensive optimization to further improve the pharmacokinetics is needed for clinical development. In the present study, we report on the design, synthesis, optimization, and in vitro and in vivo evaluations of a series of potent CRBN-based PROTAC KRAS degraders. We focused evaluations of our designed KRAS degraders on KRASG12D and KRASG12V mutants since these two mutations together account for more than half of all KRAS-driven cancers. Starting from potent, pan KRAS inhibitors and a novel and high-affinity CRBN ligand, we have discovered two highly potent and efficacious KRAS degraders, namely CW-10201 and CW-10203. Both compounds effectively induced degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cells and attained IC50 values of 2–5 nM in inhibition of cell growth in SW1990 and SW620 cancer cell lines carrying KRASG12D or KRASG12V mutation. CW-10201 induced tumor regression in the SW1990 KRASG12D xenograft model in mice with weekly intravenous administration and effectively inhibited tumor growth in the SW620 KRASG12V xenograft model at well tolerated dose-schedules. CW-10201 represents a promising degrader targeting both KRASG12D and KRASG12V mutants for further optimization for advanced preclinical development and future clinical trials. Results and Discussion Design of a High-Affinity and Novel Tetracyclic Cereblon Ligand AA-17010 KRAS degraders, including compound 8, have been developed using a CRBN E3 ligand. , These previously reported KRAS degraders , designed using a CRBN ligand were capable of achieving excellent degradation potency and potent cell growth inhibition in SW620 cells harboring KRASG12V mutation with IC50 < 20 nM, indicating that CRBN ligands can be employed for the development of potent and effective KRAS degraders. We sought to design novel cereblon ligands with high affinities to cereblon to expand the opportunities to develop potent and efficacious KRAS degraders. Kymera disclosed compounds 10 and 11 as a new class of high-affinity cereblon ligands, which have been employed for the discovery and development of potent and efficacious PROTAC degraders. Previously, we have developed novel cereblon ligands by cyclization of lenalidomide and thalidomide to improve degradation potency and ADME/T properties of PROTAC degraders , Using a similar design strategy, we designed and synthesized AA-17010 (12) by replacing the piperazine of ligand 11 with a piperidine and cyclizing it to form a spirocyclic ring. In a competitive binding-affinity assay, AA-17010 (12) displayed a 13-fold improvement in its binding affinity to cereblon compared to lenalidomide. Based upon their IC50 values, AA-17010 (12) is 10.7-, 14.9-, 3.7- and 6.1-times more potent than lenalidomide, ligands 9, 10 and 11 (Figure ), respectively. Design of AA-17010 (12) as a novel tetracyclic cereblon ligand and its binding affinity to cereblon. Lenalidomide, ligands 9, 10 and 11 were included as controls in binding experiments. Binding affinity to cereblon for each ligand was determined in three independent experiments in triplicate. Data are presented as mean ± SEM. For binding curves, one representative experiment is depicted. Design of KRAS PROTAC Degraders As indicated above, MRTX1133 was discovered as the first-in-class KRASG12D inhibitor. , Based upon MRTX1133, extensive medicinal chemistry efforts have been made to develop both novel KRASG12D inhibitors, as well as pan KRAS inhibitors. Additionally, potent KRASG12D and pan KRAS PROTAC degraders have been reported. , We synthesized three previously disclosed KRAS degraders, namely compounds 8, 13, and 14 from a patent publication and included these degraders as controls in our investigations. Degrader 8 was synthesized using ligand 9, whereas degraders 13 and 14 were synthesized using ligands 10 and 11, respectively. We synthesized compound 15 using the same KRAS inhibitor and the linker used in 8 but replaced the cereblon ligand in 8 with AA-17010. In our KRAS HiBiT degradation assays, degrader 8 attained DC50 values of 26.7 nM and 35.3 nM, respectively, against KRASG12D and KRASG12V. In comparison, compound 15 achieved DC50 values of 31.6 nM and 26.3 nM, respectively, against KRASG12D and KRASG12V. Hence, compounds 8 and 15 have very similar degradation potencies against both KRAS mutants. We synthesized compound 16 by replacing the (R)-3-methylpiperidin-3-ol moiety in compound 15 with (S)-1-oxa-6-azaspiro­[3.5]­nonane. In our HiBiT assays, compound 16 achieved DC50 values of 19.6 nM and 17.4 nM, respectively, against KRASG12D and KRASG12V. Hence, compound 16 is slightly more potent than compound 15. We replaced the cereblon ligand in compound 13 with AA-17010, which yielded compound 17. Compound 17 displayed DC50 values of 6.7 nM and 7.8 nM, respectively, against KRASG12D and KRASG12V and is therefore a potent degrader against both KRAS mutants. Interestingly, while compound 17 is a more potent degrader against KRASG12V than compounds 13 and 14, it has a similar degradation potency against KRASG12D as compared to compounds 13 and 14. Replacement of the (R)-3-methylpiperidin-3-ol moiety in compound 17 with (S)-1-oxa-6-azaspiro­[3.5]­nonane resulted in compound 18, which achieved DC50 values of 4.0 nM against both KRASG12D and KRASG12V mutants. Hence, compound 18 (CW-10201) is more potent than compound 17 against KRASG12D and KRASG12V mutants. Based upon the potent degradation activity against both KRASG12D and KRASG12V mutants for compounds 17 and 18, we performed further optimization of their linker. Replacing the 4-fluoro-4-methylpiperidine moiety with 7-azaspiro[3.5]­nonane in compounds 17 and 18 yielded compounds 19 and 20, respectively. While both 19 and 20 are potent degraders against both KRASG12D and KRASG12V mutants with DC50 values less than 20 nM, they are less potent than compounds 17 and 18. Removal of the cyclo-propyl group in the linker of compound 17 generated compound 21, which is a weaker degrader against both KRAS mutants. Changing the cyclo-propyl group in the linker in compound 18 with cyclo-butyl led to compound 22. While compound 22 is an equally potent KRASG12D degrader as compared to compound 18, it is a much less potent KRASG12V degrader than compound 18. Installation of di-F substitutions onto the cyclo-propyl moiety in the linker in compound 18 generated compound 23, which is a similarly potent KRASG12D degrader compared to compound 18 but is a much less potent KRASG12V degrader than compound 18. We next made further modifications of the KRAS inhibitor portion in compound 18 with the data summarized in Table . We replaced the (S)-1-oxa-6-azaspiro­[3.5]­nonane moiety in compound 18 with the same moiety used in MRTX1133, a selective KRASG12D inhibitor, which yielded compound 24. As expected, compound 24 is a selective KRASG12D degrader but is less potent than compound 18. Replacing the ethyl substitution on the naphthalene ring in compound 18 with an ethynyl group, which has been employed in the development of pan and selective KRAS inhibitors, , led to compound 25. Compound 25 is equally potent against KRASG12D as compared to compound 18 but much weaker against KRASG12V than compound 18. We replaced the substituted naphthalene group in compound 18 with a substituted 1H-indazole, resulting in compound 26, which is a reasonably potent KRASG12D degrader with DC50 = 40.8 nM but shows no appreciable degradation activity against KRASG12V mutant at concentrations up to 1,000 nM. Potent pan KRAS inhibitors have been developed, in which R2 and R3 groups were fused to form a ring. We therefore synthesized compounds 27, 28 and 29 using the same fused ring for R2 and R3 groups but different R1 groups (Table ). Compound 27 attained DC50 values of 3.7 nM and 4.8 nM, respectively, against KRASG12D and KRASG12V and is equally potent as compared to compound 18. While compound 28 is a potent KRASG12D degrader with DC50 = 5.7 nM, it is only a moderately potent KRASG12V degrader with DC50 = 62.6 nM. Compound 29 is a weak degrader against both KRASG12D and KRASG12V. Hence, our modifications of the KRAS inhibitor portion identified compounds 27 (CW-10203) as a potent KRASG12D and KRASG12V degrader. Evaluation of Antiproliferative Activity in a 3D Cell Viability Assay We evaluated these degraders in Tables and for their antiproliferative activity in a three-dimensional (3D) cell viability assay in SW1990 (with KRASG12D mutation) and SW620 (with KRASG12V mutation) cell lines, with the corresponding inhibitors (compounds 30 and 31) and degraders (compounds 13 and 14) included as the controls, with the data summarized in Table . 1Design of KRAS Degraders Based on Degraders 8, 13 and 14 and CRBN Ligand 12 aDegradation potency for each synthesized KRAS degrader was evaluated against KRAS G12D and G12V proteins using HiBiT assays in three independent experiments in triplicate. Design of KRAS Degraders Based on Degraders 8, 13 and 14 and CRBN Ligand 12 Degradation potency for each synthesized KRAS degrader was evaluated against KRAS G12D and G12V proteins using HiBiT assays in three independent experiments in triplicate. 2Investigation of Different KRAS Inhibitors for the Design of KRAS Degraders aDegradation potency for each synthesized KRAS degrader was evaluated against KRAS G12D and G12V proteins using HiBiT assays in three independent experiments in triplicate. Investigation of Different KRAS Inhibitors for the Design of KRAS Degraders Degradation potency for each synthesized KRAS degrader was evaluated against KRAS G12D and G12V proteins using HiBiT assays in three independent experiments in triplicate. 3Cell Viability Inhibition of KRAS Degraders and Control KRAS Inhibitors in SW620 (KRASG12V) and SW1990 (KRASG12D) Cancer Cell Lines IC50 ± SEM (nM)Compound No.SW1990SW620 30 (PG-5-6)4.7 ± 0.318.3 ± 4.7 31 (CW-10197)32.8 ± 2.499.0 ± 18.7 13 (Compound 65)7.7 ± 4.214.8 ± 6.3 14 (Compound 64)2.2 ± 0.64.7 ± 1.3 15 (CW-10149)7.3 ± 1.511.2 ± 2.4 16 (CW-11013)4.0 ± 1.08.0 ± 2.0 17 (CW-10176)5.3 ± 1.09.8 ± 1.6 18 (CW-10201)1.7 ± 0.23.9 ± 0.9 19 (CW-11014)3.5 ± 1.35.8 ± 1.4 20 (CW-10310)5.0 ± 2.68.1 ± 1.9 21 (PG-5-76)53.4 ± 17.0104 ± 18.7 22 (PG-5-208)7.9 ± 1.514.7 ± 2.4 23 (CW-10298)11.1 ± 0.416.7 ± 1.2 24 (PG-5-209)6.8 ± 2.1>1000 25 (CW-10267)10.1 ± 2.112.1 ± 2.6 26 (CW-10230)605 ± 177297 ± 45 27 (CW-10203)3.8 ± 0.45.5 ± 1.0 28 (CW-10278)31.2 ± 4.237.1 ± 5.4 29 (CW-11060)452 ± 149637 ± 164aCells were treated with different compounds with different concentrations for 6 days in three independent experiments in triplicate. Cell viability was determined in a cell Titer-Glo assay. Cell Viability Inhibition of KRAS Degraders and Control KRAS Inhibitors in SW620 (KRASG12V) and SW1990 (KRASG12D) Cancer Cell Lines Cells were treated with different compounds with different concentrations for 6 days in three independent experiments in triplicate. Cell viability was determined in a cell Titer-Glo assay. Several of these degraders display single digit nM IC50 values in both SW1990 and SW620 cell lines, including compounds 16, 17, 18, 19, 20 and 27. Consistent with their degradation activity against both KRASG12D and KRASG12V, 18 (CW-10201) and 27 (CW-10203) are two of the most potent compounds based upon their cell growth inhibition activity in both cancer cell lines. While 18 (CW-10201) achieved IC50 values of 1.7 nM and 3.9 nM in SW1990 and SW620 cell lines, respectively, 27 (CW-10203) achieved IC50 values of 3.8 nM and 5.5 nM in SW1990 and SW620 cell lines, respectively. In direct comparison, 18 (CW-10201) is 3- and 5-times more potent than its corresponding KRAS inhibitor compound 30 in SW1990 and SW620 cell lines, respectively, and 27 (CW-10203) is 9- and 18-times more potent than its corresponding KRAS inhibitor compound 31 in SW1990 and SW620 cell lines, respectively. Both compounds 18 and 27 are several times more potent than compound 13 in both KRAS mutant cell lines. However, compound 18 is only slightly more potent than the other reference degrader 14. Based upon their potent degradation and cell growth inhibition activity, compounds 18 (CW-10201) and 27 (CW-10203) were selected for further evaluation. Pharmacokinetics of CW-10201 and CW-10203 in Mice CW-10201 and CW-10203 were evaluated for their pharmacokinetics in mice with compounds 13 and 14 included as the controls, with PK data summarized in Table . 4Pharmacokinetic (PK) Parameters of Compound 13, 14, CW-10201 and CW-10203 in MiceCompound No.Intravenous Dose (mg/kg) T 1/2 (h) C max (ng/mL)AUC(0–t) (h·ng/mL)Vss (L/kg)Cl (mL/h/kg) 13 2.04.0 ± 0.12731 ± 2854563 ± 6181.5 ± 0.1440 ± 58 14 2.04.3 ± 0.42362 ± 7551562 ± 763.0 ± 0.31274 ± 63 CW-10201 2.07.7 ± 1.5836 ± 1222557 ± 5115.7 ± 1.3740 ± 160 CW-10203 2.020.5 ± 12.5670 ± 1014041 ± 5077.4 ± 1.6315 ± 116 Pharmacokinetic (PK) Parameters of Compound 13, 14, CW-10201 and CW-10203 in Mice Both CW-10201 and CW-10203 demonstrated excellent PK profiles, characterized by slow clearance (Cl = 740 and 315 mL/h/kg, respectively), high plasma exposure (AUC(0–t) values of 2557 and 4041 h·ng/mL, respectively), excellent volume of distribution (Vss = 5.7 and 7.4 L/kg, respectively), and a long elimination half-life (T 1/2 = 7.7 and 20.5 h, respectively). Compounds 13 and 14 also displayed good PK profiles, characterized by slow clearance (Cl = 440 and 1274 mL/h/kg, respectively), high plasma exposure (AUC(0–t) values of 4563 and 1562 h·ng/mL, respectively), good volume of distribution (Vss = 1.5 and 3.0 L/kg, respectively), and a relatively long elimination half-life (T 1/2 = 4.0 and 4.3 h, respectively). In direct comparison, both CW-10201 and CW-10203 had a longer elimination half-life (T 1/2 = 7.7 and 20.5 h, respectively) than compounds 13 and 14 (T 1/2 = 4.0 and 4.3 h, respectively). Furthermore, both CW-10201 and CW-10203 had a higher volume of distribution (Vss = 5.7–7.4 L/kg) than compounds 13 and 14 (vs 1.5–3.0 L/kg), suggesting more extensive tissue distribution, which is beneficial for the treatment of solid tumors. Pharmacodynamic Evaluation of CW-10201 and CW-10203 in SW1990 (G12D) and SW620 (G12V) Xenograft Models Based upon its potent in vitro degradation activity and excellent PK profiles for CW-10201, we investigated its pharmacodynamics (PD) in the SW1990 KRASG12D human pancreatic cancer xenograft model in mice, with the data summarized in Figure . Pharmacodynamic study and drug concentrations of CW-10201 in SW1990 tumors in SCID mice. Mice were treated with a single IV dose at 60 mg/kg. Tumor tissues were collected at indicated time-points of 24, 48, 96, and 168 h. (A) Western blotting analysis of the levels of KRASG12D protein in the SW1990 tumor tissues. ß-Actin was used as the loading control. (B) Quantification of KRASG12D protein levels in tumor tissue. (C) Concentrations of CW-10201 in plasma and tumor tissue in mice in the PD experiment shown in (A). Data were provided as mean ± SD. A single intravenous dose of CW-10201 (60 mg/kg) induced robust and sustained depletion of KRASG12D protein in the tumor tissue (Figure ). At 24, 48, and 96 h after the drug administration, the level of KRASG12D protein in the tumor tissue was reduced by >80% over the vehicle control tumor (Figure ). Impressively, even at 168 h (7 days) after the drug treatment, the level of KRASG12D protein in the tumor tissue was markedly reduced by 74% over the vehicle control tumor (Figure ). We analyzed the drug concentrations in plasma and tumor tissue for CW-10201 with data summarized in Figure . In plasma, CW-10201 retained a reasonable drug level of 559 ng/mL at 24 h but displayed low drug concentrations (<100 ng/mL) at 48, 96, and 168 h. In tumor, CW-10201 attained a high drug level at all the four time points. Even at 168 h, CW-10201 still attained a drug concentration of 965 ng/g. Hence, CW-10201 demonstrated excellent tumor tissue penetration and much slower clearance from tumor than from plasma. We further evaluated CW-10201 and CW-10203 for their pharmacodynamics in the SW620 KRASG12V human colorectal cancer xenograft tumor model in mice with data summarized in Figure . A single, intravenous administration of CW-10201 at 30 mg/kg reduced the levels of KRASG12V protein by approximately 50% at 6, 24, and 48 h. However, CW-10201 only reduced the levels of KRASG12V protein modestly (20%) at 96 h time-point and had no effect at 168 h time-point. In comparison, CW-10203 at 30 mg/kg had similar effects on the levels of KRASG12V protein, capable of reducing the protein levels by approximately 50% at 6, 24, and 48 h time-points but displaying much less effect at 96 and 168 h time-points (Figure ). Pharmacodynamic study and drug concentrations of CW-10201 and CW-10203 in SW620 tumor bearing mice. Mice were treated with a single IV dose at 30 mg/kg. Tumor tissues were collected at indicated time-points of 6, 24, 48, 96, and 168 h. (A–B) Western blotting analysis of KRASG12V protein levels in SW620 tumor tissue. β-Actin was used as the loading control. (C) Quantification of KRASG12V protein levels in SW620 tumor tissues. (D) Quantification of pERK1/2 levels in SW620 xenograft tumors. (E) Analysis of drug concentrations of CW-10201 and CW-10203 in plasma and tumor tissues from the pharmacodynamic experiment shown in panel (A–B). Data were presented as mean ± SD. We analyzed the drug concentrations in plasma and SW620 tumors for CW-10201 and CW-10203 with data summarized in Figure . Both CW-10201 and CW-10203 showed reasonably high plasma concentration at 6 h time-point but had much lower plasma concentration at 24 h time-point and thereafter. In the SW620 tumor tissue, both CW-10201 and CW-10203 had higher drug concentrations than in the plasma at 6, 24, and 48 h time-points but displayed low drug level at 96 and 168 h time-points. The drug exposure data in SW1990 and SW620 tumor tissues are consistent with their in vivo degradation data for both compounds. Degradation of KRAS protein is expected to result in inhibition of pERK1/2 activity. Our Western blot analysis (Figure ) showed that the levels of pERK1/2 were reduced by 70% at 6 and 24 h time-points for both CW-10201 and CW-10203 and 50% at 48 h in the SW620 tumor tissue. Consistent with the degradation kinetics, both CW-10201 and CW-10203 only modestly inhibited pERK1/2 at 96 and 168 h time-points in the SW620 tumor tissue. Efficacy Studies of CW-10201 and CW-10203 We evaluated the in vivo antitumor activity of CW-10201 in the SW1990 human pancreatic cancer xenograft model with data summarized in Figure . Because a single administration of CW-10201 was capable of inducing KRASG12D protein depletion for 7 days, CW-10201 was administered weekly at 30 or 60 mg/kg intravenously when tumors reached approximately 240 mm3. Our efficacy data showed that CW-10201 was very effective in inhibition of tumor growth and capable of achieving tumor regression. After the second dose of CW-10201, 51% of tumor regression was observed in the 30 mg/kg group and 67% of tumor regression was achieved in the 60 mg/kg group (Figure A). Throughout the entire efficacy experiment, there was no significant weight loss or other signs of toxicity observed in all treatment groups, indicating that CW-10201 was well tolerated at doses up to 60 mg/kg (Figure B). Efficacy study of CW-10201 in the KRASG12D xenograft tumor model in mice (mean ± SEM, n = 8 for the vehicle control group and n = 5 for CW-10201 treatment groups). (A) Tumor growth in the SW1990 mouse xenograft model. Mice bearing SW1990 tumors were treated once a week with CW-10201 via intravenous injection at indicated doses. (B) Percentage of body weight change in the SW1990 mouse xenograft model. Tumor volumes and body weights of mice were measured every 3 to 4 days. For the control group of mice, measurement of tumor size and animal body weight was discontinued on day 38 because some mice had to be euthanized due to excessive tumor burden. Statistical analysis was performed using two-tailed unpaired Student’s t-tests. Both treatment groups in the SW1990 xenograft study were significantly different from the vehicle control on day 38 (P < 0.0001). Our PD data showed that a single, intravenous administration of CW-10201 and CW-10203 at 30 mg/kg effectively reduced the KRASG12V protein level in the SW620 xenograft tumors for 48 h but had much less effect at 96 h and thereafter. Accordingly, we evaluated CW-10201 and CW-10203 for their antitumor efficacy in the SW620 xenograft tumor model in mice with twice weekly intravenous administration at 30 mg/kg with the data summarized in Figure . When tumor volumes reached an average of 105 mm3, mice were treated with CW-10201 or CW-10203 at 30 mg/kg twice a week for 4 weeks intravenously via tail injection. Both compounds effectively inhibited tumor growth and maintained comparable efficacy throughout the study. On day 36, CW-10201 and CW-10203 achieved a tumor growth inhibition (TGI) of 73–74% (Figure A). Both compounds were well tolerated with the twice-weekly dosing schedule and induced minimal weight loss over the control treatment (Figure B). Efficacy study for CW-10201 and CW-10203 in the SW620 KRASG12V xenograft tumor model in mice (mean ± SEM, n = 8). (A) Tumor growth in the SW620 mouse xenograft model. Mice bearing SW620 tumors were treated twice a week with CW-10201 and CW-10203 via intravenous injection at 30 mg/kg. (B) Percentage of body weight change in the SW620 xenograft model in mice. Both tumor volumes and body weights of mice were measured every 3 to 4 days. For the control group of mice, measurement of tumor size and animal body weight was discontinued on day 36 because some mice had to be euthanized due to excessive tumor burden. Statistical analysis was performed using two-tailed unpaired Student’s t-tests. Both treatment groups in the SW620 xenograft study were significantly different from vehicle control on day 36 (P < 0.001). Evaluation of CW-10201 and CW-10203 for Their Neo-Substrate Activity CW-10201 and CW-10203 were designed using a potent cereblon ligand and thus have the potential to induce degradation of neo-substrates for CRBN such as IKZF1 and GSPT1. We therefore evaluated their activity in inducing degradation of IKZF1 and GSPT1 using HiBiT assays. Our data showed that CW-10201 and CW-10203 failed to induce any degradation of IKZF1 and GSPT1 proteins at concentrations up to 1 μM (SI Figure S5). Chemistry The synthesis of AA-17010 (12) is outlined in Scheme . Intermediate 34 was prepared from 2-bromo-4-fluoro-5-nitrophenol (32) and tert-butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1­(2H)-carboxylate (33) via a Mitsunobu reaction, followed by nucleophilic aromatic substitution with methylamine to afford intermediate 35. Reduction of the nitro group using NH4Cl and Zn produced amine 36, which was subsequently treated with CDI to give compound 37. An AIBN-mediated radical cyclization then furnished spiro intermediate 38. Reaction of 38 with 3-bromopiperidine-2,6-dione (39), followed by Boc deprotection with TFA, yielded AA-17010 (12). Finally, reductive amination and deprotection steps afforded a series of linker-AA-17010 analogs (42a–c). Synthetic Route of Compound 12 (AA-17010) and Linker-AA-17010 Fragments aReagents and conditions: (a) DIAD (1.5 eq.), triphenylphosphine (1.5 eq.), THF, rt, o/n, 89%; (b) MeNH2 (4 eq., 2 M in THF), DIEA (3 eq.), DCM, rt, o/n, 95%; (c) MeOH/H2O, NH4Cl, Zn, rt, 2 h; (d) CDI (2.6 eq.), DMF, 3 h, 55% for 2 steps; (e) AIBN (0.1 eq.), Bu3SnH (3 eq.), toluene, reflux, 76%; (f) 1) LHMDS (6 eq., 1 M in THF), THF, 0 °C, 30 min; 2) 39 (4.0 eq.), 70 °C o/n; (g) TFA:DCM (1:1), 15 min, 45% for 2 steps; (h) NaBH­(OAc)3, DMF, rt, overnight; (i) TFA/DCM (1:1, v/v), rt, 70–90% for 2 steps. Reagents and conditions: (a) DIAD (1.5 eq.), triphenylphosphine (1.5 eq.), THF, rt, o/n, 89%; (b) MeNH2 (4 eq., 2 M in THF), DIEA (3 eq.), DCM, rt, o/n, 95%; (c) MeOH/H2O, NH4Cl, Zn, rt, 2 h; (d) CDI (2.6 eq.), DMF, 3 h, 55% for 2 steps; (e) AIBN (0.1 eq.), Bu3SnH (3 eq.), toluene, reflux, 76%; (f) 1) LHMDS (6 eq., 1 M in THF), THF, 0 °C, 30 min; 2) 39 (4.0 eq.), 70 °C o/n; (g) TFA:DCM (1:1), 15 min, 45% for 2 steps; (h) NaBH­(OAc)3, DMF, rt, overnight; (i) TFA/DCM (1:1, v/v), rt, 70–90% for 2 steps. Key intermediate 51a–b were made as reported, followed by reductive amination with 42a–c and deprotection afforded compounds 15–20 (Scheme ). Synthetic Route of Compounds 15–20 aReagents and conditions: (a) DIEA (3 eq.), DCM, −40 °C, 1 h, 95%; (b) NaH (1.1 eq.), THF, 0 °C–rt, 2 h, 88%; (c) K2CO3 (3 eq.), Catacxium A-Pd-G3 (0.2 eq.), dioxane:H2O (4:1), 100 °C, 3 h; (d) TBAF (1 M in THF), 4 h, 76% for 2 steps; (e) DMP (1.5 eq.), DCM, 0 °C–rt, 2 h, 90%; (f) Acetic acid, DMF: Titanium isopropoxide (5:1, v/v), NaCNBH3 (10 eq.), rt, o/n; (g) TFA:DCM (3:1), 1.5 h. Reagents and conditions: (a) DIEA (3 eq.), DCM, −40 °C, 1 h, 95%; (b) NaH (1.1 eq.), THF, 0 °C–rt, 2 h, 88%; (c) K2CO3 (3 eq.), Catacxium A-Pd-G3 (0.2 eq.), dioxane:H2O (4:1), 100 °C, 3 h; (d) TBAF (1 M in THF), 4 h, 76% for 2 steps; (e) DMP (1.5 eq.), DCM, 0 °C–rt, 2 h, 90%; (f) Acetic acid, DMF: Titanium isopropoxide (5:1, v/v), NaCNBH3 (10 eq.), rt, o/n; (g) TFA:DCM (3:1), 1.5 h. Intermediate 54 was made as reported, followed by Suzuki coupling to afford Intermediate 55. Subsequent oxone oxidation and reaction with 46 yielded 57. After removal of TBS, DMP oxidation gave the aldehyde 59. Reductive amination and deprotection afforded CW-10203 (Scheme ). Synthetic Route of Compounds 27 (CW-10203)­ aReagents and conditions: (a) 1) DIEA (1.17 eq.), THF, 0 °C, 1 h; 2) LiOtBu (3 eq., 1 M in THF), 50 °C, 40 min, 94%; (b) K2CO3 (3 eq.), RuPhos-Pd-G3 (0.12 eq.), dioxane:H2O (10:1, v/v), 95 °C, o/n; (c) oxone (2.25 eq.), acetone:sat. NaHCO3 (1:1, v/v), 30 min; (d) lithium trimethylsilanolate (3.5 eq.), CH3CN, 50 °C, 30 min, 46%; (e) TBAF (1 M in THF), 4 h; (f) DMP (1.5 eq.), DCM, 0 °C–rt, 2 h, 90%; (g) acetic acid (cat.), DMF:Titanium isopropoxide (5:1, v/v), NaCNBH3 (10 eq.), rt, o/n; (h) TFA:DCM (3:1), 1.5 h. Reagents and conditions: (a) 1) DIEA (1.17 eq.), THF, 0 °C, 1 h; 2) LiOtBu (3 eq., 1 M in THF), 50 °C, 40 min, 94%; (b) K2CO3 (3 eq.), RuPhos-Pd-G3 (0.12 eq.), dioxane:H2O (10:1, v/v), 95 °C, o/n; (c) oxone (2.25 eq.), acetone:sat. NaHCO3 (1:1, v/v), 30 min; (d) lithium trimethylsilanolate (3.5 eq.), CH3CN, 50 °C, 30 min, 46%; (e) TBAF (1 M in THF), 4 h; (f) DMP (1.5 eq.), DCM, 0 °C–rt, 2 h, 90%; (g) acetic acid (cat.), DMF:Titanium isopropoxide (5:1, v/v), NaCNBH3 (10 eq.), rt, o/n; (h) TFA:DCM (3:1), 1.5 h. Conclusion KRAS mutations represent one of the most frequent oncogenic driver mutations in lethal cancers. In pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and lung adenocarcinoma (LUAD), KRAS mutation rates account for 90%, 45%, and 34%, respectively. The FDA approvals of two KRASG12C inhibitors Sotorasib and Adagrasib have provided critical clinical validation that KRAS mutations can be successfully targeted therapeutically. To date, no drugs have been approved to target KRASG12D and KRASG12V mutations, which together account for more than 50% of all KRAS mutant cancers. In addition to conventional small-molecule inhibitors and “molecular glue” inhibitors, PROTAC KRAS degraders represent another promising therapeutic strategy to target KRAS mutations and may offer several potential advantages. For example, by achieving deep degradation of KRAS mutations in cancer tissues, PROTAC KRAS degraders have the potential to eliminate the scaffold functions associated with KRAS mutations. In addition, degradation of KRAS mutations may elicit stronger antitumor immune response than KRAS inhibition. , In the present study, we sought to develop PROTAC degraders with the capability of effectively targeting both KRASG12D and KRASG12V mutations. Using a series of previously reported KRAS inhibitors, which were shown to effectively inhibit both KRASG12D and KRASG12V mutations and a novel and high-affinity cereblon ligand, we have discovered several highly potent and effective degraders of KRASG12D and KRASG12V, with CW-10201 and CW-10203 as two of the most promising compounds. Our data demonstrated that linker lengths and compositions play a key role for degradation potencies for both KRAS mutations. Interestingly, while some degraders are potent in inducing degradation of KRASG12D, they are much less potent in inducing degradation of KRASG12V. In comparison, CW-10201 and CW-10203 are equally potent in inducing degradation of both KRASG12D and KRASG12V and attained DC50 values of 4–5 nM. Consistently, CW-10201 and CW-10203 are similarly potent and effective in inhibition of cell growth in the SW1990 pancreatic cancer cell line carrying KRASG12D mutation and in the SW620 colorectal cancer cell line carrying KRASG12V mutation and achieved IC50 values of 2–5 nM. Both CW-10201 and CW-10203 exhibit excellent pharmacokinetics with intravenous administration in mice, characterized by slow clearance, high plasma exposure, a long elimination half-life, and an excellent volume of distribution. Our pharmacodynamic (PD) data showed that a single dose of CW-10201 and CW-10203 at 30 mg/kg was capable of effectively inducing depleting of KRASG12V protein in the SW620 xenograft tumors for at least 48 h. Consistently, administration of CW-10201 and CW-10203 twice a week at 30 mg/kg inhibited tumor growth by >70%. Interestingly, although CW-10201 has similar cell growth inhibition activities in the SW620 and SW1990 cancer cell lines, it is much more effective in inducing depletion of KRASG12D protein in the SW1990 xenograft tumor tissue. A single intravenous administration of CW-10201 at 60 mg/kg was capable of depletion KRASG12D protein for >80% for 4 days and >70% for 1 week in the SW1990 tumor tissue. Consistent with the strong and persistent PD effect, weekly administration of CW-10201 at both 30 and 60 mg/kg attained tumor regression in the SW1990 KRASG12D xenograft model. Interestingly, our analysis showed that CW-10201 has much higher drug concentrations in the SW1990 KRASG12D tumor tissue than those in the SW620 KRASG12V tumor tissue, particularly at time-points after 48 h, consistent with its stronger and more persistent depletion of KRASG12D protein in the SW1990 tumors than that of KRASG12V protein in the SW620 tumors. Of significance, both compounds were well tolerated in mice and induced minimal weight loss or other signs of toxicity. Because CW-10201 employed a potent CRBN ligand, we evaluated its potential activity against GSPT1 and IKZF1, two neo-substrates for CRBN. Our data showed that CW-10201 has no activity against these two CRBN neo-substrates. Collectively, our data demonstrates that CW-10201 and CW-10203 represent two promising lead compounds for further evaluation and optimization toward clinical development of a potent KRAS degrader for the treatment of human cancers carrying KRASG12D and KRASG12V mutations. Additional experiments will be conducted to evaluate the activity and efficacy for CW-10201 and CW-10203 and their improved analogues against tumors carrying other KRAS mutations. Experimental Section General Information for Chemistry Unless otherwise noted, all commercial materials were used as received. NMR spectra were recorded on a Bruker Ascend 400 MHz spectrometer and calibrated using residual solvent peaks as internal reference. In reported spectral data, the format (δ) chemical shift (multiplicity, J values in Hz, integration) was used with the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, dd = doublet of doublets, and m = multiplet. Mass spectrometric (MS) analysis was carried out with a Waters UPLC ACQUITY QDa mass spectrometer. Flash column chromatography was performed by Teledyne CombiFlash RF+ using RediSep Rf silica gel flash column. The final compounds were all purified by a C18 reverse phase preparative HPLC column (SunFire Prep C18 OBD 5 μm, 50 × 100 mm) with solvent A (0.1% TFA or formic acid in H2O) and solvent B (0.1% TFA or formic acid in MeCN) as eluents at 60 mL/min flow rate. The purity of all the final compounds was measured and confirmed to be >95% by UPLC-MS analysis (10–100% MeCN in H2O containing 0.1% formic acid in 10 min, 0.610 mL/min flow rate) with a C18 column (ACQUITY UPLC BEH C18 1.7 μm, 2.1 × 50 mm). All final compounds are made by following the general synthetic method of Titanium isopropoxide catalyzed reductive amination followed by deprotection with TFA. Dissolved both the aldehyde and amine intermediates in a mixture of DMF and titanium isopropoxide (5:1, v/v), followed by adding acetic acid and allowed to stir for 15 min, then add 10 eq. of saturated solution of NaCNBH3 in THF. The reaction mixture is allowed to stir overnight, upon completion, quenched by water then filtered with Celite and washed with methanol. After concentration of the filtrate under reduced pressure, the residue is purified by reverse phase combiflash, followed by deprotection with TFA in DCM to give the final compounds. 3-(1-Methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (AA-17010) tert-Butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1­(2H)-carboxylate (33) To a solution of tert-butyl 1-oxa-6-azaspiro­[2.5]­octane-6-carboxylate (6 g, 28.1 mmol) in anhydrous toluene (225 mL) was added aluminum isopropoxide (8.6 g, 42.1 mmol) and the mixture was allowed to stir at 120 °C for 72 h. The reaction was allowed to cool to room temperature and then poured into cold aqueous hydrogen chloride (0.5 M). The aqueous phase was extracted into EtOAc, and the combined organic extract was washed with 1 M NaHCO3 solution. The organic extract was dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with 0–70% EtOAc/hexane to give the title compound as colorless liquid (4.8 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ 5.64 (dq, J = 3.0, 1.5 Hz, 1H), 4.06–3.98 (m, 2H), 3.90 (dt, J = 3.1, 1.4 Hz, 2H), 3.57–3.42 (m, 2H), 2.15–2.06 (m, 2H), 1.46 (s, 9H). tert-Butyl 4-((2-bromo-4-fluoro-5-nitrophenoxy)­methyl)-3,6-dihydropyridine-1­(2H)-carboxylate (34) To a stirred solution of tert-butyl 4-(hydroxymethyl)-3,6-dihydropyridine-1­(2H)-carboxylate (33) (213 mg, 1.0 mmol, 1 eq.), 2-bromo-4-fluoro-5-nitrophenol (32) (260 mg, 1.1 mmol, 1.1 eq.) and triphenylphosphine (393 mg, 1.5 mmol, 1.5 eq.) in tetrahydrofuran (8 mL) was added diisopropyl azodicarboxylate (303 mg, 1.5 mmol, 1.5 eq.) dropwise at 0 °C under nitrogen. The reaction mixture was allowed to stir at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with 0–40% EtOAc/hexane to give the title compound (400 mg, 90% yield). tert-Butyl 4-((2-bromo-4-(methylamino)-5-nitrophenoxy)­methyl)-3,6-dihydropyridine-1­(2H)-carboxylate (35) Methylamine (1.86 mL, 3.712 mmol, 2.0 M in THF) followed by DIEA (0.472 mL, 2.784 mmol) were added to a 2 mL DCM solution of tert-butyl 4-((2-bromo-4-fluoro-5-nitrophenoxy)­methyl)-3,6-dihydropyridine-1­(2H)-carboxylate (34) (400 mg, 0.928 mmol). The reaction mixture is allowed to be stirred overnight at room temperature. Upon completion the solvent was removed and purified by column chromatography to give the title compound 35 (393 mg, 0.912 mmol, 98%). Chemical Formula: C18H24BrN3O5, Exact Mass: 441.09. LC/MS: 331.2 [M-Boc+H]+. tert-Butyl 4-((5-amino-2-bromo-4-(methylamino)­phenoxy)­methyl)-3,6-dihydropyridine-1­(2H)-carboxylate (36) A solution of ammonium chloride (285 mg, 5.34 mmol) in water (5 mL) was added to a solution of intermediate 35 (118 mg, 0.266 mmol) dissolved in methanol (15 mL). To this mixture, zinc (174 mg, 2.66 mmol) was added and the reaction was vigorously stirred. After 2 h, the yellow color disappeared and UPLC/QDa showed the reaction was complete. The reaction was concentrated, quenched with sodium hydroxide (1M), and extracted three times with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate, filtered and concentrated to give crude title compound 36 that was used without further purification. tert-Butyl 4-(((6-bromo-1-methyl-2-oxo-2,3-dihydro-1H-benzo­[d]­imidazol-5-yl)­oxy)­methyl) −3,6-dihydropyridine-1­(2H)-carboxylate (37) To a solution of 36 (111 mg crude product, 0.27 mmol, 1 eq.) in DMF (2 mL) was added carbonyldiimidazole (112 mg, 0.69 mmol, 2.5 eq.) and the mixture was allowed to stir at room temperature for 1 h. Additional carbonyldiimidazole (87 mg, 0.54 mmol, 2 eq.) was added at room temperature and the reaction was allowed to stir for 4 h. The reaction was quenched with saturated sodium bicarbonate solution and the mixture was extracted with EtOAc. The combined organic extract was washed with brine, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 0–20% MeOH/CH2Cl2 to afford the title compound 37 (64 mg, 0.146 mmol, 54% yield). tert-Butyl 1-methyl-2-oxo-2,3-dihydro-1H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidine]-1′-carboxylate (38) To a solution of compound 37 (64 mg, 0.15 mmol, 1.0 eq.) in toluene (2 mL) were added, n Bu3SnH (0.12 mL, 0.45 mmol, 3.0 eq.) and AIBN (2.5 mg, 0.015 mmol, 0.1 eq.) at room temperature. The mixture was stirred at 115 °C for 14 h. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography eluting with 0–60% CH2Cl2/EtOAc and then 0–8% MeOH/CH2Cl2 to afford the title compound 38 (53 mg, 98% yield). tert-Butyl 3-(2,6-dioxopiperidin-3-yl)-1-methyl-2-oxo-2,3-dihydro-1H,6H-spiro­[benzofuro­[5,6-d ]­imidazole-7,4′-piperidine]-1′-carboxylate ( 40 ) To a stirred solution of compound 38 (53 mg, 0.14 mmol, 1.0 eq.) in anhydrous THF (5 mL) was added 1 M LiHMDS in THF (0.84 mL, 0.84 mmol, 6 eq.) at 0 °C under nitrogen. The mixture was allowed to stir for 30 min under the same conditions. Then 3-bromopiperidine-2,6-dione 39 (108 mg, 0.56 mmol, 4 eq.) was added in one portion at 0 °C under nitrogen and the reaction mixture was allowed to stir at 70 °C for 12 h under nitrogen. The reaction mixture was cooled to room temperature, quenched with ice–water and extracted with EtOAc. The combined organic extract was dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by Prep HPLC (SunFire Prep C18 column, 50 × 100 mm, 5 μm; 25–45% MeCN/H2O + 0.1% FA; 60 mL/min) to afford the title compound 40 as white solid (40 mg, 60% yield). LCMS (ESI): m/z [M+H] calcd for C24H30N4O6 471.22; found 471.0. 3-(1-Methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (12) To a stirred solution of 40 (40 mg, 0.069 mmol, 1.0 eq.) in CH2Cl2 (1 mL) was added TFA (1 mL) at room temperature and the reaction mixture was allowed to stir at room temperature for 0.25 h. The mixture was evaporated under reduced pressure and the residue was dissolved in MeCN-H2O (1:5). The solution was freeze-dried to afford TFA salt of 12 as off-white solid (32 mg, 0.066 mmol, 96% yield). 1H NMR (400 MHz, MeOD) δ 7.04 (s, 1H), 6.67 (s, 1H), 5.27 (dd, J = 12.5, 5.5 Hz, 1H), 4.50 (s, 2H), 3.47 (dt, J = 13.3, 3.9 Hz, 2H), 3.41 (s, 3H), 3.15 (td, J = 13.1, 3.2 Hz, 2H), 2.93–2.85 (m, 1H), 2.84–2.74 (m, 2H), 2.16 (ddt, J = 12.5, 10.4, 3.8 Hz, 3H), 1.98 (d, J = 14.6 Hz, 2H). LCMS (ESI): m/z [M+H] calcd for C19H22N4O4 371.17; found 371.0. 3-(1-Methyl-2-oxo-1′-(piperidin-4-ylmethyl)-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (42a) Chemical Formula: C25H33N5O4, Exact Mass: 467.25. LC-MS: [M+H]+ = 468.3. 3-(1′-((4-Fluoropiperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (42b) 1H NMR (400 MHz, Methanol-d 4) δ 7.02 (s, 1H), 6.67 (s, 1H), 5.28 (dd, J = 12.4, 5.4 Hz, 1H), 4.48 (d, J = 2.0 Hz, 2H), 3.68 (dd, J = 24.7, 17.4 Hz, 4H), 3.46 (ddd, J = 13.6, 4.3, 2.1 Hz, 2H), 3.39 (d, J = 1.1 Hz, 3H), 3.35 (t, J = 1.6 Hz, 1H), 3.27 (dd, J = 13.1, 3.1 Hz, 3H), 2.99–2.82 (m, 1H), 2.77 (dd, J = 14.6, 4.4 Hz, 2H), 2.41 (tt, J = 9.9, 3.6 Hz, 4H), 2.23–2.02 (m, 3H), 2.01–1.88 (m, 2H). 13C NMR (101 MHz, Methanol-d 4) δ 174.61, 171.53, 156.48, 155.80, 130.46, 127.69, 125.86, 104.20, 93.29, 92.49, 90.71, 53.80, 44.17, 40.50, 40.48, 32.22, 30.83, 30.61, 27.62, 23.69. Chemical Formula: C25H32FN5O4, Exact Mass: 485.24. LC-MS: [M+H]+ = 486.3. 3-(1-Methyl-2-oxo-1′-(7-azaspiro­[3.5]­nonan-2-yl)-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6- d ]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (42c) 1H NMR (400 MHz, Methanol-d 4) δ 6.98 (s, 1H), 6.69 (s, 1H), 5.30 (dd, J = 12.3, 5.4 Hz, 1H), 4.49 (s, 2H), 3.74 (s, 1H), 3.53 (d, J = 12.6 Hz, 2H), 3.42 (s, 3H), 3.22 (t, J = 5.8 Hz, 2H), 3.19–3.10 (m, 2H), 3.01–2.71 (m, 5H), 2.51–2.38 (m, 2H), 2.27 (t, J = 11.0 Hz, 4H), 2.21–2.10 (m, 1H), 2.08–1.81 (m, 6H). 13C NMR (101 MHz, Methanol-d 4) δ 174.59, 171.49, 156.48, 155.82, 130.50, 127.72, 125.87, 104.01, 93.31, 80.82, 56.22, 53.80, 44.69, 42.45, 42.15, 36.07, 35.56, 34.16, 33.01, 32.23, 31.27, 27.63, 23.71. Chemical Formula: C27H35N5O4, Exact Mass: 493.27. LC-MS: [M+H]+ = 494.3. (R)-1-(2,7- D ichloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (45a) To a solution of 2,4,7-trichloro-8-fluoropyrido­[4,3-d]­pyrimidine (6 g, 23.8 mmol) in DCM (20 mL) was added DIEA (10.1 g, 78.5 mmol) and (R)-3-methylpiperidin-3-ol hydrochloride (3.97 g, 26.2 mmol) under nitrogen at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum and the residue was purified by flash chromatography on silica gel with PE:EA = 2:1 to give the desired compound (7.3 g, 92.6 % yield) as a white solid. Chemical Formula: C13H13Cl2FN4O, Exact Mass: 330.05. LC-MS: [M+H]+ = 330.8. (S)-6-(2,7-Dichloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane­(45b) To a solution of 2,4,7-trichloro-8-fluoropyrido­[4,3-d]­pyrimidine (700 mg, 2.77 mmol) in DCM (12 ml.) was added 3 eq. of DIEA (1.07 g, 8.31 mmol) and 0.9 eq. of (S)-1-oxa-6-azaspiro­[3.5]­nonane (343 mg, 2.70 mmol) under nitrogen at −40 °C. The reaction mixture was stirred at −40 °C for 1 h. Upon completion the reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over anhydrous Na2SO4. The solution was concentrated in vacuum and the residue was purified by flash column chromatography using a gradient from 0 to 100% of EtOAc in hexane to obtain (S)-6-(2,7-dichloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane as a white solid (900 mg, 2.62 mmol, 95%). Chemical Formula: C14H13Cl2FN4O, LC/MS: [M+H]+ = 342.9. (R)-1-(2-((1-(((tert-Butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-chloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (47a) To a solution of (1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methanol (5.4 g, 24.7 mmol) in THF (50 ml.) was added NaH (1.9 g, 60 %, 47.5 mmol) at 0 oC. The mixture was stirred at 0 °C for 15 minutes and (R)-1-(2,7-dichloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (6.3 g, 19.0 mmol) was added. The reaction mixture was stirred at 25 oC for 2 h. The reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash chromatography on silica gel with PE:EA = 1:1 to give the desired compound (7.8 g, 80.5% yield) as a white solid. Chemical Formula: C24H36ClFN4O3Si, Exact Mass: 510.22. LC-MS: [M+H]+ = 510.8. (S)-6-(2-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-chloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane (47b) To a solution of 2.5 eq. of (l-(((tert-butyldirnethylsilyl)­oxy)­methyl)­cyclopropyl)­methanol (1417 mg, 6.55 mmol) in THF (12 ml) was added NaH (115 mg, 60 % purity, 2.88 mmol) at 0 °C. The mixture was stirred at 0 °C for 15 minutes then (S)-6-(2,7-dichloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1 oxa-6-azaspiro[3.5]­nonane (900 mg, 2.62 mmol) was added. The reaction mixture was stirred at 25 oC for 2 h. Upon completion it was quenched with water and extracted with EA. The organic phase was washed with brine and dried over anhydrous Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash column chromatography using a gradient from 0 to 100% of EtOAc in hexane to give the desired compound (1.207 g, 88% yield) as a white solid. Chemical Formula: C25H36ClFN4O3Si, Exact Mass: 522.22. LC/MS: [M+H]+ = 523.0. (R)-1-(2-((1-(((tert-Butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (49a) To a solution of (R)-1-(2-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-chloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (1.052 g, 2.06 mmol) and 1.35 eq. of 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.00 g, 2.78 mmol) in dioxane (8 mL) and H2O (2 mL) was added 3 eq. of K3PO4 (1.37 g, 6.45 mmol) and 0.2 eq. of Catacxium A-Pd-G3 (313 mg, 0.43 mmol). The mixture was stirred under N2 at 95 °C for 12 h. The reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash chromatography on silica gel with EA:HEX to give the desired compound (1.3 g, 1.84 mmol, 89% yield) as a yellow solid. Chemical Formula: C38H50F2N4O5Si, Exact Mass: 708.35. LC-MS: [M+H]+ = 709.1. (S)-6-(2-((1-(((tert-Butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane (49b) To a solution of (S)-6-(2-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-chloro-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane (607 mg, 1.16 mmol) and 1.5 eq. of 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-l-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (627 mg, 1.74 mmol) in dioxane (6 mL) and H2O (1.5 mL) was added potassium carbonate (480 mg, 3.48 mmol) and Catacxium A-Pd-G3 (168 mg, 0.23 mmol). The mixture was stirred under N2 atmosphere at 100 °C for 3 h. Upon completion the reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over anhydrous Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash column chromatography using a gradient from 0 to 100% of EtOAc in hexane to give the title compound as a white solid. Chemical Formula: C39H50F2N4O5Si, Exact Mass: 720.35. LC/MS: [M+H]+ = 721.1. (R)-1-(7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-2-((1-(hydroxymethyl)­cyclopropyl)­methoxy)­pyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (50a) To a solution of (R)-1-(2-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (1.3 g, 1.84 mmol) in DMF (8 mL) was added 12 eq. CsF (3.35 g, 22.1 mmol) at room temperature. The mixture was stirred under N2 at 40 oC for 12 h. The reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash chromatography on silica gel with EA:HEX (∼80–90% EA) to give the desired compound (940 mg, 1.58 mmol, 86% yield) as an oil. Chemical Formula: C32H36F2N4O5, Exact Mass: 594.27. LC-MS: [M+H]+ = 595.1. E­(S)-(1-(((7-(8-ethyl-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-4-(1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methanol (50b) To a solution of (S)-6-(2-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoropyrido­[4,3-d]­pyrimidin-4-yl)-1-oxa-6-azaspiro­[3.5]­nonane obtained in the previous step in THF (12 mL) was added TBAF-THF (1 M, 3 mL). The mixture was stirred at room temperature for 4 h. Upon completion the reaction was quenched with water and extracted with EA. The organic phase was washed with brine and dried over anhydrous Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash column chromatography using a gradient from 0 to 100% of EtOAc in hexane to give the desired compound (521 mg, 0.89 mmol, 76% yield for 2 steps) as a white solid. Chemical Formula: C33H36F2N4O5, Exact Mass: 606.27. LC/MS: [M+H]+ = 607.1. (R)-1-(((7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-4-(3-hydroxy-3-methylpiperidin-1-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropane-1-carbaldehyde (51a) To a solution of (R)-1-(7-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-2-((1-(hydroxymethyl)­cyclopropyl)­methoxy)­pyrido­[4,3-d]­pyrimidin-4-yl)-3-methylpiperidin-3-ol (940 mg, 1.58 mmol) in DCM (15 mL) that previously cooled with ice bath was added 1.5 eq. of Dess-Martin reagent (1.01 g, 2.37 mmol). The mixture was stirred at 25 °C for 1 h, then 0.5 eq. of extra DMP was added. After another 20-30 mins, upon completion the reaction mixture was loaded directly to a cartridge and purified by flash chromatography on silica gel with EA:HEX (∼75-80% EA) to give the desired compound (720 mg, 1.21 mmol, 77% yield) as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 9.22 (s, 1H), 9.16 (d, J = 6.8 Hz, 1H), 7.68 (dd, J = 8.9, 5.7 Hz, 1H), 7.51 (d, J = 2.7 Hz, 1H), 7.27–7.24 (m, 1H), 7.21 (d, J = 2.8 Hz, 1H), 5.31–5.27 (m, 2H), 4.81–4.68 (m, 3H), 4.51–4.38 (m, 2H), 3.51 (s, 3H), 3.44 (t, J = 12.5 Hz, 1H), 3.31 (dd, J = 20.2, 13.5 Hz, 1H),2.67 (d, J = 27.6 Hz, 1H), 2.51 (dd, J = 13.4, 6.5 Hz, 1H), 2.27–2.17 (m, 1H), 2.15–2.06 (m, 1H), 1.90 (d, J = 13.3 Hz, 1H), 1.78 (s, 1H), 1.68 (dd, J = 11.2, 6.6 Hz, 1H), 1.39–1.35 (m, 3H), 1.34–1.32 (m, 2H), 0.84 (td, J = 7.4, 4.4 Hz, 3H). Chemical Formula: C32H34F2N4O5, Exact Mass: 592.25. LC-MS: [M+H]+ = 593.0. (S)-1-(((7-(8-Ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-4-(1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropane-1-carbaldehyde (51b) To a solution of (S)-(1-(((7-(8-ethyl-3-(methoxymethoxy)­naphthalen-1-yl)-8-fluoro-4-(1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methanol (521 mg, 0.89 mmol) in DCM (12 mL) was added 1.5 eq. of Dess-Martin reagent (566 mg, 1.34 mmol). The mixture was stirred at 25 °C for 1 h. Upon completion the reaction was quenched with saturated Na2S2O3 solution and extracted with DCM. The solution was concentrated in vacuum, and the residue was purified by flash column chromatography using a gradient from 0 to 100% of EtOAc in hexane to give the desired compound (467 mg, 0.80 mmol, 90% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.25 (s, 1H), 9.24 (d, J = 3.5 Hz, 1H), 7.67 (dd, J = 9.0, 5.8 Hz, 1H), 7.51 (d, J = 2.7 Hz, 1H), 7.27–7.25 (m, 1H), 7.23–7.22 (m, 1H), 5.30 (t, J = 4.2 Hz, 2H), 4.79–4.70 (m, 3H), 4.58 (dq, J = 12.5, 6.2, 5.7 Hz, 3H), 4.52–4.38 (m, 1H), 4.31–4.18 (m, 1H), 3.73 (dd, J = 20.0, 13.4 Hz, 1H), 3.51 (d, J = 1.2 Hz, 3H), 3.50–3.40 (m, 1H), 2.53 (dd, J = 15.8, 7.5 Hz, 1H), 2.49–2.42 (m, 3H), 2.32–2.25 (m, 1H), 2.21 (ddd, J = 14.7, 7.8, 3.7 Hz, 1H), 1.98–1.75 (m, 3H), 1.39 −1.35 (m, 2H), 1.34–1.30 (m, 3H), 0.84 (q, J = 7.4 Hz, 3H). Chemical Formula: C33H34F2N4O5, Exact Mass: 604.25. LC/MS: [M+H]+ = 605.0. 3-(1′-((1-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)­piperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-10149) 1H NMR (400 MHz, Methanol-d4) δ 9.28 (d, J = 5.3 Hz, 1H), 7.67 (q, J = 6.2, 5.7 Hz, 1H), 7.30 (d, J = 4.7 Hz, 1H), 7.24 (t, J = 9.4 Hz, 1H), 7.06 (t, J = 2.6 Hz, 1H), 6.94 (s, 1H), 6.67 (s, 1H), 5.28 (dd, J = 12.4, 5.3 Hz, 1H), 4.60 (d, J = 12.9 Hz, 1H), 4.55–4.41 (m, 4H), 4.33 (t, J = 12.5 Hz, 1H), 3.93 (s, 2H), 3.76–3.55 (m, 4H), 3.52–3.43 (m, 2H), 3.39 (s, 4H), 3.23–2.97 (m, 6H), 2.89 (dd, J = 18.1, 5.7 Hz, 1H), 2.79 (d, J = 14.8 Hz, 2H), 2.51–2.07 (m, 10H), 2.07–1.93 (m, 3H), 1.84 (d, J = 22.3 Hz, 5H), 1.33 (d, J = 7.5 Hz, 2H), 1.28 (d, J = 14.7 Hz, 2H), 1.02 (s, 2H), 0.94–0.87 (m, 2H), 0.82 (q, J = 7.0 Hz, 3H). Chemical Formula: C55H63F2N9O7, Exact Mass: 999.48. LC-MS: [M+H]+ = 1000.3. 3-(1′-((1-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((S)-1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)­piperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione­(CW-11013) 1H NMR (400 MHz, Methanol-d 4) δ 9.29 (d, J = 7.1 Hz, 1H), 7.67 (dd, J = 9.1, 5.8 Hz, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.24 (t, J = 9.3 Hz, 1H), 7.08 (t, J = 2.9 Hz, 1H), 6.96 (s, 1H), 6.61 (s, 1H), 5.27 (dd, J = 12.5, 5.4 Hz, 1H), 4.94 (s, 1H), 4.81–4.43 (m, 7H), 4.40 (s, 2H), 3.93–3.66 (m, 3H), 3.54–3.41 (m, 1H), 3.39 (s, 3H), 3.18 (dd, J = 23.1, 9.7 Hz, 2H), 3.06–2.85 (m, 4H), 2.85–2.68 (m, 2H), 2.60–2.37 (m, 4H), 2.37–1.89 (m, 11H), 1.81 (dd, J = 8.6, 4.2 Hz, 1H), 1.74 (d, J = 13.3 Hz, 2H), 1.60 (t, J = 12.8 Hz, 2H), 1.31 (d, J = 17.3 Hz, 2H), 1.10–0.67 (m, 7H). Chemical Formula: C56H63F2N9O7, Exact Mass: 1011.48. LC-MS: [M+H]+ = 1012.4. 3-(1′-((1-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)-4-fluoropiperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-10176) 1H NMR (400 MHz, Methanol-d 4) δ 9.33 (d, J = 13.2 Hz, 1H), 7.64 (dd, J = 9.1, 5.7 Hz, 1H), 7.28 (d, J = 2.4 Hz, 1H), 7.22 (t, J = 9.3 Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 6.98 (s, 1H), 6.66 (s, 1H), 5.28 (dd, J = 12.3, 5.3 Hz, 1H), 4.63 (d, J = 13.0 Hz, 1H), 4.59–4.44 (m, 4H), 4.35 (t, J = 11.8 Hz, 1H), 3.98 (s, 1H), 3.87 (s, 1H), 3.76–3.56 (m, 5H), 3.47 (t, J = 11.7 Hz, 2H), 3.38 (s, 4H), 3.26 (d, J = 12.8 Hz, 2H), 2.90 (ddd, J = 18.5, 14.1, 4.9 Hz, 1H), 2.83–2.70 (m, 2H), 2.61–2.31 (m, 7H), 2.26 (dq, J = 9.4, 4.2, 2.3 Hz, 1H), 2.14 (dt, J = 9.6, 4.9 Hz, 2H), 1.93 (d, J = 14.9 Hz, 2H), 1.83 (t, J = 12.0 Hz, 3H), 1.31 (d, J = 6.3 Hz, 4H), 1.11–0.97 (m, 2H), 0.92 (h, J = 6.8, 6.4 Hz, 2H), 0.82 (td, J = 7.3, 3.5 Hz, 3H). Chemical Formula: C55H62F3N9O7, Exact Mass: 1017.47. LC-MS: [M+H]+ = 1018.4. 3-(1′-((1-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((S)-1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)-4-fluoropiperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-10201) 1H NMR (400 MHz, Methanol-d 4) δ 9.30 (d, J = 9.4 Hz, 1H), 7.61 (ddd, J = 8.6, 5.9, 2.0 Hz, 1H), 7.25 (d, J = 2.6 Hz, 1H), 7.17 (td, J = 9.4, 6.1 Hz, 1H), 7.06 (t, J = 2.9 Hz, 1H), 6.85 (d, J = 5.2 Hz, 1H), 6.60 (d, J = 1.6 Hz, 1H), 5.28 (dd, J = 12.4, 5.4 Hz, 1H), 4.81–4.42 (m, 6H), 4.35 (s, 2H), 3.93–3.63 (m, 3H), 3.53–3.32 (m, 3H), 3.31 (s, 3H), 3.24 (t, J = 13.3 Hz, 2H), 3.03–2.85 (m, 3H), 2.85–2.71 (m, 2H), 2.66 (s, 1H), 2.60 (s, 1H), 2.57–2.38 (m, 3H), 2.37–1.87 (m, 13H), 1.87–1.74 (m, 1H), 1.60 (d, J = 13.0 Hz, 2H), 1.00 (d, J = 2.3 Hz, 2H), 0.94–0.71 (m, 5H). 13C NMR (101 MHz, Methanol-d 4) δ 174.64, 171.50, 165.60, 156.57, 155.83, 154.39, 135.54, 130.16, 129.74, 128.91, 125.50, 124.30, 117.62, 117.34, 113.57, 112.39, 104.23, 85.70, 85.47, 81.64, 74.21, 66.46, 60.40, 53.84, 53.77, 45.34, 37.29, 37.21, 32.25, 31.29, 31.20, 27.56, 23.80, 22.24, 22.02, 17.36, 14.97, 11.75. Chemical Formula: C56H62F3N9O7, Exact Mass: 1029.47. LC-MS: [M+H]+ = 1030.3. 3-(1′-(7-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((R)-3-hydroxy-3-methylpiperidin-1-yl)­pyrido­[4,3-d]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)-7-azaspiro­[3.5]­nonan-2-yl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-11014) 1H NMR (400 MHz, DMSO-d 6) δ 11.05 (s, 1H), 9.96 (s, 1H), 9.24 (s, 1H), 8.14 (s, 1H), 7.77 (dd, J = 9.1, 5.9 Hz, 1H), 7.44–7.28 (m, 2H), 7.02 (d, J = 2.7 Hz, 2H), 6.70 (s, 1H), 6.53 (s, 1H), 5.30 (dd, J = 12.8, 5.4 Hz, 1H), 4.72 (d, J = 5.1 Hz, 1H), 4.49–4.24 (m, 5H), 4.07 (dd, J = 20.2, 13.2 Hz, 1H), 3.64 (d, J = 13.1 Hz, 1H), 3.60–3.37 (m, 5H), 3.07 (s, 4H), 2.93–2.79 (m, 2H), 2.72 (td, J = 12.6, 4.2 Hz, 2H), 2.65–2.52 (m, 2H), 2.43–2.25 (m, 2H), 2.24–1.90 (m, 8H), 1.73 (dd, J = 33.4, 18.0 Hz, 9H), 1.37–1.06 (m, 4H), 0.75 (tt, J = 25.5, 13.0 Hz, 7H). Chemical Formula: C57H65F2N9O7, Exact Mass: 1025.50. LC-MS: [M+H]+ = 1026.4. 3-(1′-(7-((1-(((7-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-4-((S)-1-oxa-6-azaspiro­[3.5]­nonan-6-yl)­pyrido­[4,3- d ]­pyrimidin-2-yl)­oxy)­methyl)­cyclopropyl)­methyl)-7-azaspiro­[3.5]­nonan-2-yl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6- d ]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-10310) 1H NMR (400 MHz, Methanol-d 4) δ 9.30 (d, J = 8.2 Hz, 1H), 7.67 (dd, J = 9.0, 5.8 Hz, 1H), 7.26 (dd, J = 20.4, 11.0 Hz, 2H), 7.08 (t, J = 2.9 Hz, 1H), 6.96 (s, 1H), 6.67 (s, 1H), 5.28 (dd, J = 12.4, 5.4 Hz, 1H), 4.90 (s, 1H), 4.71 (dd, J = 34.0, 13.7 Hz, 2H), 4.57 (q, J = 7.2, 6.6 Hz, 2H), 4.50 (d, J = 7.9 Hz, 4H), 3.94–3.67 (m, 4H), 3.53 (d, J = 12.4 Hz, 3H), 3.41 (s, 3H), 3.37 (d, J = 6.6 Hz, 1H), 3.19–2.99 (m, 2H), 2.89 (dd, J = 16.6, 8.0 Hz, 3H), 2.84–2.70 (m, 2H), 2.63–2.43 (m, 4H), 2.38–2.14 (m, 8H), 2.00 (td, J = 22.5, 20.6, 13.2 Hz, 8H), 1.82 (dd, J = 10.7, 6.5 Hz, 1H), 1.31 (d, J = 17.0 Hz, 1H), 1.01 (s, 2H), 0.88 (s, 2H), 0.82 (td, J = 7.4, 4.0 Hz, 3H). 13C NMR (101 MHz, Methanol-d 4) δ 174.50, 171.33, 166.29, 165.03, 156.35, 155.75, 154.31, 145.57, 135.49, 130.42, 128.92, 127.57, 126.45, 125.81, 124.29, 117.33, 113.59, 103.87, 93.21, 80.68, 74.42, 66.37, 63.71, 59.90, 56.07, 53.70, 51.53, 51.10, 44.60, 37.13, 37.05, 34.06, 33.40, 32.13, 31.17, 31.05, 27.52, 23.62, 22.11, 20.05, 16.95, 14.85, 11.73. Chemical Formula: C58H65F2N9O7, Exact Mass: 1037.47. LC-MS: [M+H]+ = 1038.4. (S)-2-Chloro-1-fluoro-12-(methylthio)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (54) An aliquot of 4,5,7-trichloro-8-fluoro-2-(methylthio)­pyrido­[4,3-d]­pyrimidine (1.47 g, 4.93 mmol) was suspended in 30 mL anhydrous acetonitrile. 1.05 eq. of DIPEA (627 mg, 4.86 mmol) was added and the suspension cooled to 0 °C in ice bath under N2 atmosphere. In a separate vial, 0.9 eq. of (R)-(1,4-oxazepan-3-yl)­methanol (582 mg, 4.44 mmol) was dissolved in 20 mL of THF. This solution was added to the flask containing the cold solution of reaction mixture. The reaction is monitored by LCMS analysis. After about 45 mins at 0 °C, upon completion of the initial reaction 3 eq. of LiOtBu (1 M in THF) was added dropwise and the ice bath was removed. The reaction was heated at 50 °C with an oil bath. Monitored by LCMS analysis, after about 2 h, upon completion the reaction mixture was cooled to rt and evaporated. Saturated aqueous NaHCO3 (40 mL) was added, and the mixture was extracted with DCM. The combined organic extract was dried over Na2SO4 and evaporated. The crude material was purified using flash chromatography eluting with a gradient of 0–100% EtOAc in hexane and using DCM to load the crude material onto the silica cartridge. Fractions containing the desired product were combined and concentrated to give the title compound (1.51 g, 4.22 mmol, 86%) as a tan solid. 1H NMR (400 MHz, Chloroform-d) δ 5.20 (ddd, J = 13.8, 6.8, 3.0 Hz, 1H), 4.65 (dd, J = 13.4, 4.5 Hz, 1H), 4.43 (dd, J = 13.5, 1.0 Hz, 1H), 4.19 (dd, J = 12.6, 3.7 Hz, 1H), 4.13–3.92 (m, 2H), 3.71 (dd, J = 12.7, 9.7 Hz, 1H), 3.34 (dddd, J = 15.9, 13.7, 9.8, 5.1 Hz, 2H), 2.60 (s, 3H), 2.24–2.14 (m, 1H), 2.09–1.91 (m, 1H). LC/MS: [M+H]+ = 356.8. (S)-2-(8-Ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-12-(methylthio)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (55) To a solution of (S)-2-chloro-1-fluoro-12-(methylthio)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (1.43 g, 4.01 mmol) and 1.5 eq. of 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.16 g, 6.01 mmol) in dioxane (22 mL) and H2O (2.2 mL) was added 3 eq. of K2CO3 (1.66 g, 12.02 mmol) and 0.12 eq. of RuPhos Pd G3 (402 mg, 0.49 mmol). The mixture was stirred under N2 atmosphere at 95 °C for 8 h. LCMS showed that the starting material had been consumed, and water was added to quench the reaction, then extracted with EA. The organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum, and the residue was purified by flash chromatography on silica gel with EA:HEX to give the title compound (1.98 g, 3.57 mmol, 89%) as a yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 7.64 (dd, J = 9.0, 5.8 Hz, 1H), 7.47 (dd, J = 2.7, 1.2 Hz, 1H), 7.30–7.16 (m, 2H), 5.27 (qt, J = 4.7, 2.1 Hz, 3H), 4.70–4.57 (m, 1H), 4.46 (ddd, J = 14.2, 13.3, 0.9 Hz, 1H), 4.23 (s, 1H), 4.04 (dt, J = 11.9, 7.1 Hz, 2H), 3.78 (ddd, J = 17.2, 12.6, 9.7 Hz, 1H), 3.50 (d, J = 1.4 Hz, 3H), 3.48–3.26 (m, 2H), 2.63 (d, J = 1.6 Hz, 3H), 2.61–2.17 (m, 3H), 2.01 (ddd, J = 11.9, 5.9, 3.1 Hz, 1H), 1.26 (t, J = 7.1 Hz, 2H), 0.92 (q, J = 7.3 Hz, 3H). LC/MS: [M+H]+ = 555.0. E­(S)-2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-12-(methylsulfonyl)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (56) To a mixture of (S)-2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-12-(methylthio)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (1.86 g, 3.35 mmol) in MEK (52 ml) was added 2.25 eq. of solid Oxone (4.64 g, 7.54 mmol), and saturated aqueous NaHCO3 (52 ml). The mixture was stirred at rt for 30 min. Upon completion the reaction mixture was diluted with EtOAc, and the aqueous layer was extracted twice more with EtOAc. The combined organic extract was washed with 10% aqueous Na2S2O3 and brine. After drying over Na2SO4, the mixture was filtered and evaporated to afford 1.57 g of the sulfone as a yellow gum. LC/MS: [M+H]+ = 587.0. This material was taken to the next step without further purification. (S)-12-((1-(((tert-Butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (57) To a mixture of (S)-2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-12-(methylsulfonyl)-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (1.42 g, 2.41 mmol) and 2.5 eq. of (1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methanol (1.31 g, 6.03 mmol) were dissolved in CH3CN (6 mL). 3.5 eq. of lithium trimethylsilanolate was added and the vial was capped, stirred and heated to 50 °C for 30 min to afford the title compound (810 mg, 1.12 mmol, 46%) as a yellow solid. LCMS: 723.1 [M+H]+. (S)-1-(((2-(8-Ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalen-12-yl)­oxy)­methyl)­cyclopropane-1-carbaldehyde (59) To a solution of (S)-12-((1-(((tert-butyldimethylsilyl)­oxy)­methyl)­cyclopropyl)­methoxy)-2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalene (810 mg, 1.12 mmol) in 8 mL THF was added 5.4 mL TBAF (1 M/L). The mixture was stirred at rt for 2 h. Upon completion the reaction was quenched with water and extracted with EA. The combined organic phase was washed with brine and dried over Na2SO4. The solution was concentrated in vacuum and the residue was purified by flash chromatography on silica gel with EA:HEX (∼80–90% EA) to give the desired compound as a pale yellow solid. LC/MS: 609.0 [M+H]+. To a solution of (S)-(1-(((2-(8-ethyl-7-fluoro-3-(methoxymethoxy)­naphthalen-1-yl)-1-fluoro-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalen-12-yl)­oxy)­methyl)­cyclopropyl)­methanol in DCM (8 mL) that previously cooled with ice bath was added 1.5 eq. of Dess-Martin reagent. The mixture was stirred at 25 °C for 1 h, then 0.3 eq. of extra DMP was added. Upon completion the reaction mixture was loaded directly to a cartridge and purified by flash chromatography on silica gel with EA:HEX (∼75–80% EA) to give the title compound (560 mg, 0.92 mmol, 82 % for 2 steps) as a yellow solid. LC/MS: 607.0 [M+H]+. 3-(1′-((1-((1-((((S)-2-(8-Ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-1-fluoro-5a,6,9,10-tetrahydro-5H,8H-4,7-dioxa-3,10a,11,13-tetraazanaphtho­[1,8-ab]­heptalen-12-yl)­oxy)­methyl)­cyclopropyl)­methyl)-4-fluoropiperidin-4-yl)­methyl)-1-methyl-2-oxo-1,2-dihydro-3H,6H-spiro­[benzofuro­[5,6-d]­imidazole-7,4′-piperidin]-3-yl)­piperidine-2,6-dione (CW-10203) 1H NMR (400 MHz, DMSO-d 6) δ 11.04 (s, 1H), 9.92 (s, 1H), 8.14 (s, 1H), 7.74 (dd, J = 9.1, 6.0 Hz, 1H), 7.50–7.19 (m, 2H), 7.20–6.88 (m, 2H), 6.64 (s, 1H), 6.53 (s, 1H), 5.28 (dd, J = 12.8, 5.4 Hz, 1H), 5.12–4.93 (m, 1H), 4.67 (dd, J = 13.4, 4.5 Hz, 1H), 4.52 (dd, J = 13.2, 4.9 Hz, 1H), 4.34 (d, J = 10.8 Hz, 5H), 4.11 (dt, J = 12.4, 4.5 Hz, 1H), 3.98–3.82 (m, 1H), 3.66 (dd, J = 12.3, 9.5 Hz, 1H), 3.57 (dd, J = 12.1, 9.9 Hz, 1H), 3.52–3.35 (m, 7H), 2.84 (d, J = 11.9 Hz, 5H), 2.76–2.52 (m, 4H), 2.48–2.21 (m, 5H), 2.16 (t, J = 11.9 Hz, 2H), 2.10–1.81 (m, 7H), 1.71 (d, J = 32.8 Hz, 2H), 1.57 (d, J = 12.4 Hz, 2H), 0.82 (dt, J = 14.2, 7.3 Hz, 3H), 0.70 (s, 2H), 0.50 (s, 2H). 13C NMR (101 MHz, MeOD) δ 172.72, 169.91, 163.74, 163.03, 159.36, 159.25, 156.15, 156.10, 155.59, 155.44, 153.91, 153.39, 152.87, 152.85, 151.97, 151.83, 146.87, 146.76, 144.74, 144.59, 144.48, 144.31, 133.58, 127.97, 127.78, 124.36, 124.25, 124.04, 123.89, 123.77, 122.86, 122.76, 116.28, 116.01, 111.80, 103.25, 99.50, 99.17, 94.10, 91.64, 79.71, 71.04, 70.03, 69.20, 68.77, 68.67, 67.42, 67.07, 63.14, 62.63, 61.88, 52.10, 51.65, 49.79, 49.56, 48.98, 43.61, 40.14, 39.93, 39.72, 39.51, 39.30, 39.09, 38.88, 36.36, 32.49, 32.38, 32.18, 31.13, 26.95, 21.85, 18.67, 14.17, 14.12, 9.56. Chemical Formula: C55H60F3N9O8, Exact Mass: 1031.45. LC/MS Found: [M+1]+: 1032.3. Cereblon Binding Assay The binding to cereblon (CRBN) was determined using the Cereblon Binding Kit (Cisbio, #64BDCRBNPEG) following the manufacturer’s instructions. Briefly, serially diluted compounds were incubated with GST-tagged wild-type human CRBN protein, XL665-labeled Thalidomide and Europium Cryptate labeled GST antibody at room temperature for ∼3 h. Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) measurements were acquired on a CLARIOstar plate reader with MARS data analysis software (BMG Labtech), with the following settings: 665/10 nm and 620/10 nm emission, 60 μs delay and 400 μs integration. The TR-FRET ratio was taken as the 665/620 nm intensity ratio. The readings were normalized to the control (0.5%), the IC50 and K i values of binding affinity were calculated by nonlinear regression (four parameters sigmoid fitted with variable slope) analysis using the GraphPad Prism 10 software. KRAS G12D, G12V, G12C HiBiT and IKZF1 and GSPT1 HiBiT Assay for Protein Degradation KRAS G12D-HiBiT KI HEK293, KRAS G12V-HiBiT KI SW620 and KRAS G12C-HiBiT KI MIA PaCa-2 cell lines, as well as IKZF1 (Ikaros) HiBiT KI Jurkat, and GSPT1 HiBiT KI HEK293 cell lines were purchased from Promega (Madison, WI, USA). Cells were seeded in 384-well plates (Corning #3765) at 2000 cells per well and incubated with serially diluted compounds for 24–48 h at 37 °C with 5% CO2. At the end of treatment, Nano-Glo HiBiT Lytic Detection reagents were added to the wells and luminescence was acquired on TECAN SPARK plate reader. Untreated cells were used as control. Data points were fitted with a four-parameter equation to generate a concentration–response curve. DC50 values were calculated using a nonlinear regression analysis of the mean ± SD from triplicate. 3D Cell Viability Assays SW1990 and SW620 cells were purchased from American Type Culture Collection (ATCC) and maintained in the RPMI1640 growth medium containing 10% FBS and 1% Penicillin Streptomycin. For cell growth assay, cells were seeded in round-bottom ultralow attachment 384-well plates (Corning 4520) at 1000–3000 cells/well in 40 μL of growth medium containing 10% FBS and 1% Penicillin, Streptomycin and then incubated at 37 °C overnight. The following day, the serially diluted compounds were added to the cells. The cells were then incubated at 37 °C for 6 days. Upon completion, 40 μL of CellTiter-Glo 3D Reagent (Promega) was added to each well. The plates were then incubated at room temperature for 30 min and luminescence was acquired on TECAN SPARK plate reader. Untreated cells were used as control. Data points were fit with a four-parameter equation to generate a concentration–response curve. IC50 values were calculated using a nonlinear regression analysis of the mean ± SD from triplicate. Pharmacokinetic (PK) Studies in Mice PK studies were performed in Shanghai Medicilon Inc., Shanghai, China. ICR mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. For each PK study for each compound, the mice were divided into two groups: 3 animals in each group were administered either vehicle control or tested compound via intravenous (IV) tail vein injection. The drug solution was freshly prepared before administration, and each compound was formulated in 5% DMSO + 10% solutol +85% saline as a clear solution. Blood samples were collected at the following time-points: 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h postdose administration. Thirty μL of blood was collected and the samples were placed in tubes containing heparin sodium and stored on ice. The samples were centrifuged at ∼6800 G for 6 min at 2–8 °C and the resulting plasma was transferred to appropriately labeled tubes within 1 h of blood collection/centrifugation and then stored frozen at −80 °C. Method development and biological sample analysis for the test articles (Sodium heparin anticoagulant) were performed by the testing facility by means of LC-MS/MS. The analytical results were confirmed using quality control samples for intra-assay variation. The accuracy of >66.7% of the quality control samples was between 80 and 120% of the known value(s). Standard set of parameters including T 1/2 (elimination half-life), AUC(0–t) and AUC(0–∞) (area-under-the-curve), C max (maximum drug concentration), and T max (time to reach maximum plasma concentration) and other parameters were calculated using Phoenix WinNonlin 7.0 (Pharsight, USA) by the Study Director. PK/PD and Efficacy Studies in Mice All in vivo studies were performed under animal protocols (PRO00011174 and PRO00009463) approved by the Institutional Animal Care & Use Committee (IACUC) of the University of Michigan, in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. SW1990 PD Studies Female CB.17 SCID mice were subcutaneously implanted with 5 × 106 SW1990 cells in 0.1 mL Matrigel on the right flank. When tumors reached a mean volume of approximately 90–110 mm3 in size, 20 mice were randomized into 5 groups, including 4 treatment groups and 1 control group. Compound CW-10201 was dissolved in DMSO: Solutol: PBS (5%: 10%: 85%, by volume) and injected into 4 mice of each treatment group with a 60 mg/kg dose via tail vein. Plasma was collected at 24, 48, 96, and 168 h, and tumor was harvested at 24, 48, 96, and 168 h after dosing to determine exposure levels. Tumor fragments were either snap frozen in homogenization tubes with liquid nitrogen for drug analysis (PK) or ground into frozen powder for Western blot analysis (PD). SW620 PD Studies Female CB.17 SCID mice were subcutaneously implanted with 5 × 106 SW620 cells in 0.1 mL Matrigel on the right flank. After inoculation, when tumors reached a mean volume of approximately 90–110 mm3 in size, 42 mice were randomized into 10 treatment groups with 3–4 mice each group and 1 control group of 4 mice. Compounds CW-10201 and CW-10203 were dissolved in DMSO: Solutol: PBS (5%: 10%: 85%, by volume) and injected all 3–4 mice of each treatment group with a 30 mg/kg dose via tail vein, respectively. Plasma was collected at 6, 24, 48, 96, and 168 h, and tumor was harvested at 6, 24, 48, 96, and 168 h after dosing, to determine exposure levels. Tumor fragments were snap frozen in homogenization tubes with liquid nitrogen and homogenized with T-PER Tissue Protein Extraction Buffer with protease and phosphatase inhibitors added fresh before use. Tumor lysates were then analyzed for ERK1/2 and phosphorylated ERK1/2 (pERK1/2). Western Blot Analysis Tumor tissues were lysed in RIPA buffer (Sigma-Aldrich, R0278). The tumor lysates were separated on Novex 16% Tris-Glycine Mini Gels (Thermo Fisher Scientific, XP00165), and transferred to a PVDF membrane (EMD Millipore, IPFL00010). PVDF membranes were first blocked with Intercept (TBS) Protein-Free Blocking Buffer (LI-COR Biosciences, 927-80001), then were incubated with these following primary antibodies: Ras (G12D Mutant Specific) (D8H7) Rabbit mAb (Cell Signaling Technology, #14429S), Ras (G12V Mutant Specific) (D2H12) Rabbit mAb (Cell Signaling Technology, #14412S) and Anti-β-Actin Mouse Monoclonal Antibody [C4] (Santa Cruz Biotechnology, sc-47778). The secondary antibodies used are goat antimouse IgG polyclonal antibody (IRDye 800CW) (LI-COR Biosciences, 926-32210) and goat antirabbit IgG polyclonal antibody (IRDye 680RD) (LI-COR Biosciences, 926-68071). Membranes were scanned and bands were quantified with Odyssey CLx Imaging System (LI-COR Biosciences). SW1990 Efficacy Studies Female CB.17 SCID mice were subcutaneously implanted with 5 × 106 SW1990 cells in 0.1 mL Matrigel on the right flank. When tumors reached a mean volume of approximately 220–250 mm3 in size, 18 mice were randomized into 2 groups for efficacy study and 1 group as control, 8 mice for the vehicle control group and 5 mice for each of CW-10201 treatment groups. Randomized mice received vehicle consisting of 25% PEG400:7.5% Cremophor EL 67.5% PBS with 0.5N NaOH (v/v/v) and compound CW-10201 at 30 mg/kg and 60 mg/kg dose by intravenous administration weekly. Animals were monitored every 3–4 days, tumor volumes were determined twice weekly in two dimensions using a caliper, expressed in mm3 using the formula: V = 0.5­(a × b2) where a and b are the long and short diameters of the tumor, respectively. Data are presented as mean tumor volume ± standard error of the mean (SEM). SW620 Efficacy Studies Female CB.17 SCID mice were subcutaneously implanted with 5 × 106 SW620 cells in 0.1 mL Matrigel on the right flank. When tumors reached a mean volume of approximately 90–110 mm3 in size, 24 mice were randomized into 2 treatment groups and 1 control group, with 8 mice for each group. CW-10201 and CW-10203 were dissolved in DMSO: Solutol: PBS (5%: 10%: 85%, by volume) and injected each treatment group twice a week with a 30 mg/kg dose via tail vein, respectively. Animals were monitored every 3–4 days, tumor volumes were determined twice weekly in two dimensions using a caliper, expressed in mm3 using the formula: V = 0.5­(a × b2) where a and b are the long and short diameters of the tumor, respectively. Data is presented as mean tumor volume ± standard error of the mean (SEM). Supplementary Material